Results 81 to 90 of about 106,290 (280)

Immunotherapy, Inflammation and Colorectal Cancer. [PDF]

open access: yes, 2020
Colorectal cancer (CRC) is the third most common cancer type, and third highest in mortality rates among cancer-related deaths in the United States.
Karin, Michael   +3 more
core   +1 more source

Primary Tumor Resection in Patients With Unresectable Metastatic Colorectal Cancer: A Systematic Review and Meta‐Analysis

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This systematic review and meta‐analysis evaluated the role of primary tumor resection (PTR) in asymptomatic patients with unresectable metastatic colorectal cancer. Across 17 eligible studies including 9317 patients, PTR did not improve overall or progression‐free survival compared with chemotherapy alone.
Junpei Takashima   +3 more
wiley   +1 more source

Metformin protects from oxaliplatin induced peripheral neuropathy in rats

open access: yesNeurobiology of Pain, 2020
Oxaliplatin is a commonly used drug to treat cancer, extending the rate of disease-free survival by 20% in colorectal cancer. However, oxaliplatin induces a disabling form of neuropathy resulting in more than 60% of patients having to reduce or ...
N.W. Martinez   +10 more
doaj   +1 more source

Intense endoplasmic reticulum stress (ERS) / IRE1α enhanced Oxaliplatin efficacy by decreased ABCC10 in colorectal cancer cells

open access: yesBMC Cancer, 2022
Background Attenuated Oxaliplatin efficacy is a challenge in treating colorectal cancer (CRC) patients, contributory to the failure in chemotherapy and the risks in relapse and metastasis.
Xiaohui Liu   +7 more
doaj   +1 more source

Preoperative Gemcitabine/Nab‐Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Although NCCN guidelines recommend preoperative therapy for borderline resectable pancreatic cancer (BR‐PC), it is still unclear which regimen is better. The study objective was to elucidate the prognostic significance of neoadjuvant chemoradiotherapy (NACRT) with gemcitabine/nab‐paclitaxel (GnP‐RT) compared to gemcitabine alone ...
Hirofumi Akita   +9 more
wiley   +1 more source

Effects of oxaliplatin on mouse myenteric neurons and colonic motility

open access: yesFrontiers in Neuroscience, 2013
Oxaliplatin, an anti-cancer chemotherapeutic agent used for the treatment of colorectal cancer, commonly causes gastrointestinal side-effects such as constipation, diarrhoea, nausea and vomiting.
Linah eWafai   +5 more
doaj   +1 more source

Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma [PDF]

open access: yes, 2018
In this study, our aim is to assess the role played by autophagy and its inhibition in the different PDAC cellular compartments, and its involvement in chemo-resistance using primary human pancreatic cancer-derived cells (PCC) and Cancer Associated ...
Bintz, Jennifer   +6 more
core   +1 more source

Advances in Gastric Cancer Research: Insights Into Carcinogenesis, the Tumor Microenvironment, Metastasis, and Factors Influencing Prognosis

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background The Department of Gastroenterological Surgery at Kumamoto University has maintained a commitment to integrating cutting‐edge clinical practice with fundamental research, particularly concerning malignant diseases of the digestive tract.
Hideo Baba   +4 more
wiley   +1 more source

Upregulation of ERK phosphorylation in rat dorsal root ganglion neurons contributes to oxaliplatin-induced chronic neuropathic pain.

open access: yesPLoS ONE, 2019
Oxaliplatin is the first-line chemotherapy for metastatic colorectal cancer. Unlike other platinum anticancer agents, oxaliplatin does not result in significant renal impairment and ototoxicity.
Toyoaki Maruta   +7 more
doaj   +1 more source

FAM129B, an antioxidative protein, reduces chemosensitivity by competing with Nrf2 for Keap1 binding. [PDF]

open access: yes, 2019
BackgroundThe transcription factor Nrf2 is a master regulator of antioxidant response. While Nrf2 activation may counter increasing oxidative stress in aging, its activation in cancer can promote cancer progression and metastasis, and confer resistance ...
Cheng, Jing-Yan   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy